X0508 4 2025-12-19 0000907654 Oruka Therapeutics, Inc. ORKA 0001756991 Goncalves Joana C/O ORUKA THERAPEUTICS, INC. 855 OAK GROVE AVE., SUITE 100 MENLO PARK CA 94025 0 1 0 0 Chief Medical Officer 1 Common Stock 2025-12-19 4 M 0 3500 6.84 A 5018 D Common Stock 2025-12-19 4 M 0 3500 7.80 A 8518 D Common Stock 2025-12-19 4 S 0 641 28.5322 D 7877 D Common Stock 2025-12-19 4 S 0 1787 29.622 D 6090 D Common Stock 2025-12-19 4 S 0 1492 30.7011 D 4598 D Common Stock 2025-12-19 4 S 0 3080 31.579 D 1518 D Employee Stock Option (right to buy) 6.84 2025-12-19 4 M 0 3500 0 D 2034-05-06 Common Stock 3500 225063 D Employee Warrant (right to buy) 7.80 2025-12-19 4 M 0 3500 0 D 2034-07-14 Common Stock 3500 196492 D Includes 191 shares acquired under the Oruka stock purchase plan on December 8, 2024, 661 shares acquired under the Oruka stock purchase plan on June 8, 2025 and 666 shares acquired under the Oruka stock purchase plan on December 8, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.14 to $29.12, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4), (5) and (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.15 to $30.13, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.20 to $31.18, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.21 to $32.00, inclusive. The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. /s/ Paul Quinlan, as attorney-in-fact for Joana Goncalves 2025-12-19